{"id":58508,"date":"2026-11-09T11:22:11","date_gmt":"2026-11-09T11:22:11","guid":{"rendered":"https:\/\/www.bridge-global.com\/blog\/?p=58508"},"modified":"2026-11-16T10:38:34","modified_gmt":"2026-11-16T10:38:34","slug":"guide-healthcare-mobile-app-development","status":"publish","type":"post","link":"https:\/\/www.bridge-global.com\/blog\/guide-healthcare-mobile-app-development\/","title":{"rendered":"Healthcare Mobile App Development: A Decision Guide"},"content":{"rendered":"<p>What determines whether a healthcare mobile app needs a medical-device review, and how should that decision shape its technology stack? The answer starts with intended use: what the software does, what it claims to do, and how patients or clinicians may rely on its output. That classification should guide architecture, integrations, security controls, testing, and team design before production development begins.<\/p>\n<h2>Healthcare Mobile App Development Starts with Intended Use<\/h2>\n<p>Would a failure in this app affect a care decision? The answer depends on what each software function is designed to do, what the product claims, and how patients or clinicians may use its output. The <a href=\"https:\/\/www.hhs.gov\/guidance\/sites\/default\/files\/hhs-guidance-documents\/FDA\/Guidance-DSF-MMA.pdf\" target=\"_blank\" rel=\"noopener\">FDA&#039;s guidance on mobile medical applications<\/a> distinguishes device functions from lower-risk uses, such as providing electronic access to a manufacturer&#039;s labeling or instructions.<\/p>\n<p>Classify functions before choosing architecture, integrations, security controls, and tests. Record intended users, inputs, outputs, claims, and the potential consequences of failure for each one. A reminder feature and a function that analyzes physiological data may sit in the same app, but they do not necessarily carry the same clinical risk.<\/p>\n\n<figure class=\"wp-block-table\"><table><tr>\n<th>App type<\/th>\n<th>Core features<\/th>\n<th>Trigger that moves it toward device rules<\/th>\n<th>Regulatory tier<\/th>\n<\/tr>\n<tr>\n<td>Patient engagement and wellness<\/td>\n<td>Appointments, education, habit tracking<\/td>\n<td>Diagnostic claims or treatment advice<\/td>\n<td>Wellness tier, privacy law applies<\/td>\n<\/tr>\n<tr>\n<td>Clinician workflow<\/td>\n<td>Secure messaging, order review, rounding<\/td>\n<td>Output used to make treatment decisions<\/td>\n<td>Clinical tier, device review if used for decision support<\/td>\n<\/tr>\n<tr>\n<td>Remote patient monitoring<\/td>\n<td>Paired device readings, alerts, care-team dashboards<\/td>\n<td>Alerts that trigger clinical action<\/td>\n<td>Device tier in most markets<\/td>\n<\/tr>\n<tr>\n<td>Mental health<\/td>\n<td>Mood tracking, guided CBT modules, crisis prompts<\/td>\n<td>Claims to diagnose or treat a condition<\/td>\n<td>Wellness or device tier, set by claims<\/td>\n<\/tr>\n<tr>\n<td>Diagnostic or AI analysis<\/td>\n<td>Image or signal analysis, risk scores<\/td>\n<td>Any output that informs diagnosis<\/td>\n<td>Device tier, EU MDR Rule 11 may place it at Class IIa or higher<\/td>\n<\/tr>\n<\/table><\/figure>\n<p>A medication reminder illustrates why intended use matters. A function that only prompts a patient to follow an existing schedule differs from one that recommends changing medication based on readings. Claims in product materials should match the function and the evidence supporting it.<\/p>\n<p>For a diagnostic software use case, image- and signal-analysis tools are clear examples of the device tier shown in the table. By contrast, <a href=\"https:\/\/www.bornbir.com\/blog\/virtual-care-tools-for-maternal-health-providers\" target=\"_blank\" rel=\"noopener\">maternal telehealth tools<\/a> illustrate a patient-facing care context. For more on engineering software intended to function as a medical device, see Bridge Global&#039;s <a href=\"https:\/\/www.bridge-global.com\/blog\/medical-device-software-development\/\">medical device software development guide<\/a>. Related topics include telemedicine app development and wearable app development for healthcare.<\/p>\n<h2>Compliance Requirements in Each Target Market<\/h2>\n<p>Compliance follows the market, data, and functions involved. The same product may face different requirements across regions, so establish target markets early and have qualified counsel confirm the applicable obligations. This planning table is an orientation, not legal advice.<\/p>\n<p><figure class=\"wp-block-image size-large\"><img decoding=\"async\" src=\"https:\/\/www.bridge-global.com\/blog\/wp-content\/uploads\/2026\/11\/healthcare-mobile-app-development-healthcare-strategy.jpg\" alt=\"A diverse team of professionals collaboratively discussing digital healthcare strategy in a modern office meeting room.\" \/><\/figure><\/p>\n\n<figure class=\"wp-block-table\"><table><tr>\n<th>Market and regime<\/th>\n<th>Trigger<\/th>\n<th>Build obligation<\/th>\n<\/tr>\n<tr>\n<td>United States, HIPAA<\/td>\n<td>A covered entity or business associate handles ePHI<\/td>\n<td>Security Rule risk analysis, safeguards and appropriate business associate agreements<\/td>\n<\/tr>\n<tr>\n<td>United States, FDA<\/td>\n<td>A software function meets the device definition<\/td>\n<td>Classification, applicable premarket review and cybersecurity documentation<\/td>\n<\/tr>\n<tr>\n<td>EU, GDPR and Dutch UAVG<\/td>\n<td>The product processes personal data of EU users<\/td>\n<td>Document a lawful basis for health-data processing, assess DPIA needs and plan data handling<\/td>\n<\/tr>\n<tr>\n<td>EU, MDR 2017\/745<\/td>\n<td>Software is intended for diagnosis, monitoring or therapy<\/td>\n<td>Assess Rule 11 classification, quality-system needs and conformity assessment<\/td>\n<\/tr>\n<tr>\n<td>UK, UK GDPR and UK MDR 2002<\/td>\n<td>The app serves UK users or is placed on the UK market as a device<\/td>\n<td>Address data-protection duties and applicable device registration and conformity routes<\/td>\n<\/tr>\n<tr>\n<td>Canada, Health Canada and PIPEDA<\/td>\n<td>The app has a medical-device function or handles commercial personal data<\/td>\n<td>Assess device-licensing requirements and privacy safeguards<\/td>\n<\/tr>\n<tr>\n<td>Apple App Store and Google Play<\/td>\n<td>The app handles health data or provides a health-related function<\/td>\n<td>Complete relevant health declarations and privacy disclosures; substantiate medical claims<\/td>\n<\/tr>\n<\/table><\/figure>\n<p>In the US, HIPAA&#039;s Security Rule applies when an app creates, receives, maintains, or transmits ePHI for a covered entity or business associate. HHS includes mobile communication apps used for telehealth or other electronic communications in the risk-analysis scope. Its <a href=\"https:\/\/www.hhs.gov\/hipaa\/for-professionals\/privacy\/guidance\/hipaa-audio-telehealth\/index.html\" target=\"_blank\" rel=\"noopener\">HIPAA guidance for audio-only telehealth<\/a> points to risks such as interception, unauthorized access to stored recordings, inadequate authentication, and sessions that remain open after inactivity.<\/p>\n<p>In the EU, health data is treated as a special category of personal data under GDPR. Teams need to establish a valid basis for processing and assess whether a data protection impact assessment is needed, particularly for large-scale processing. The Netherlands also has the UAVG. For device software, assess the MDR classification and conformity route. In the UK and Canada, device functions can bring additional market-specific requirements, so don&#039;t assume that a US classification settles the question elsewhere.<\/p>\n<p><strong>Before development starts:<\/strong><\/p>\n<ul>\n<li><p><strong>Name the initial markets:<\/strong> Record where the app will be offered and where data will be processed.<\/p>\n<\/li>\n<li><p><strong>Map data and functions:<\/strong> Identify health data, device features, and clinical claims.<\/p>\n<\/li>\n<li><p><strong>Confirm obligations with counsel:<\/strong> Resolve classification, privacy, and conformity questions before fixing release scope.<\/p>\n<\/li>\n<\/ul>\n<h2>Pick a Native or Cross-Platform Stack for Clinical Use<\/h2>\n<p>For many wellness and patient-engagement apps, a cross-platform framework is a reasonable starting point. Apps that rely on continuous Bluetooth sensors, background health-data synchronization, or substantial device-specific behavior may need native code or native modules. The device tier matters: if a function falls under device rules, each third-party dependency can add validation work.<\/p>\n\n<figure class=\"wp-block-table\"><table><tr>\n<th>Criterion<\/th>\n<th>Swift and Kotlin, native<\/th>\n<th>Flutter or React Native<\/th>\n<\/tr>\n<tr>\n<td>HealthKit and Health Connect access<\/td>\n<td>First-party APIs, documented from launch<\/td>\n<td>Plugins are available; check maintenance and feature coverage<\/td>\n<\/tr>\n<tr>\n<td>Background sync and BLE pairing<\/td>\n<td>Direct control over platform background modes and Bluetooth<\/td>\n<td>Common cases are supported; edge cases can require native modules<\/td>\n<\/tr>\n<tr>\n<td>Shared codebase<\/td>\n<td>Separate app codebases or shared logic in a module<\/td>\n<td>One codebase for most screens<\/td>\n<\/tr>\n<tr>\n<td>Device-software validation<\/td>\n<td>Fewer third-party components to assess<\/td>\n<td>Each plugin needs an assessment and documentation<\/td>\n<\/tr>\n<tr>\n<td>Team skills<\/td>\n<td>Dedicated iOS and Android engineering skills<\/td>\n<td>A smaller team can cover both platforms<\/td>\n<\/tr>\n<tr>\n<td>Wellness-app release work<\/td>\n<td>Separate platform release trains<\/td>\n<td>Shared UI changes can ship through one codebase<\/td>\n<\/tr>\n<\/table><\/figure>\n<p>Make the choice against the hardest requirement in the first release, not the easiest screen to build. First, list the device APIs, sensors, and background tasks the app needs. Next, review each plugin&#039;s maintenance history, platform coverage, and open issues. Finally, choose the stack that meets the hardest requirement with the fewest unvalidated components. Pin plugin versions and record each third-party component in the risk file.<\/p>\n<p>A symptom tracker with shared screens and straightforward data entry can suit a cross-platform stack. A remote-monitoring product that receives continuous sensor streams may need native modules for its data layer, even if the rest of the interface is shared. For a team considering external engineering support, Bridge Global&#039;s <a href=\"https:\/\/www.bridge-global.com\/services\/mobile-application-development\">mobile application development service<\/a> is relevant to this build decision.<\/p>\n<h2>Connect FHIR, EHRs and Device Health Data<\/h2>\n<p>Start with the data contract. FHIR support isn&#039;t a checkbox; the app needs an agreed definition of what data means, where it comes from, and how the care workflow handles it. ONC&#039;s SAFER System Management guidance recommends documenting API data specifications and responsibilities, using interoperability standards such as FHIR and HL7 C-CDA, and testing beyond successful API calls. It also calls for attention to degraded networks, duplicate or malformed data, authentication, and post-release monitoring. See the <a href=\"https:\/\/healthit.gov\/clinical-quality-and-safety\/safer-guides\" target=\"_blank\" rel=\"noopener\">ONC SAFER Guides<\/a>.<\/p>\n<ol>\n<li><p><strong>Define the data elements:<\/strong> For every inbound and outbound field, specify its meaning, source of truth, permitted use, retention, and owner.<\/p>\n<\/li>\n<li><p><strong>Read the EHR&#039;s CapabilityStatement:<\/strong> Agree on the FHIR version, supported profiles, and any continuing HL7 v2 or C-CDA exchanges. FHIR resources such as Patient, Observation, and MedicationRequest need correct identifiers, references, terminology, and authorization scopes.<\/p>\n<\/li>\n<li><p><strong>Choose read-only or bidirectional access:<\/strong> Writes can create clinical obligations. Assign ownership for abnormal results, alerts, and clinician follow-up before sending data into the EHR.<\/p>\n<\/li>\n<li><p><strong>Request health data by type:<\/strong> Apple HealthKit and Android Health Connect rely on user permissions for data types. Users can revoke permission, so build for missing or incomplete records. A practical example of a product flow involving <a href=\"https:\/\/getlila.com\/features\/apple-health\" target=\"_blank\" rel=\"noopener\">syncing health data with Apple Health<\/a> helps illustrate why consent and user control belong in the design.<\/p>\n<\/li>\n<li><p><strong>Treat vendor SDKs and aggregators as dependencies:<\/strong> Test their latency, duplicate readings and format conversions, then monitor data-quality exceptions after launch.<\/p>\n<\/li>\n<\/ol>\n<p>ONC reported that 57% of US individuals used an app to access their online medical records in 2024, up from 51% in 2022, and that 81% of US hospitals enabled patient access through apps configured to meet EHR API specifications. These figures describe patient access apps, not clinician workflows, according to <a href=\"https:\/\/healthit.gov\/data\/data-briefs\/individuals-access-and-use-patient-portals-and-smartphone-health-apps-2024\/\" target=\"_blank\" rel=\"noopener\">ONC&#039;s patient-access data brief<\/a> and <a href=\"https:\/\/healthit.gov\/data\/data-briefs\/growth-health-it-enabled-patient-engagement-capabilities-among-us-hospitals-2021\/\" target=\"_blank\" rel=\"noopener\">hospital capability data<\/a>.<\/p>\n<p>FHIR connectivity alone doesn&#039;t settle identity matching, consent, terminology mapping, or who responds to an abnormal result. Use LOINC and SNOMED CT where appropriate, and measure reconciliation, duplicate records, clinician response time, and data completeness after launch. Bridge Global&#039;s <a href=\"https:\/\/www.bridge-global.com\/healthcare\/tools-and-integrations\">healthcare integrations<\/a> address the connected-system context; our <a href=\"https:\/\/www.bridge-global.com\/blog\/healthcare-api-integration-playbook\/\">healthcare API integration playbook<\/a> covers integration decisions, while the IoT application case describes a healthcare IoT application.<\/p>\n<p><figure class=\"wp-block-image size-large\"><img decoding=\"async\" src=\"https:\/\/www.bridge-global.com\/blog\/wp-content\/uploads\/2026\/11\/healthcare-mobile-app-development-fhir-integration.jpg\" alt=\"A diagram outlining a five-step process for integrating FHIR, electronic health records, and medical device data.\" \/><\/figure><\/p>\n<h2>Security Controls Tied to Clinical Risk<\/h2>\n<p>Security added at the end of a build is too late for a regulated product. A stolen session can expose a patient record, while a compromised data pipeline can produce a reading that affects care. FDA guidance expects cybersecurity risk analysis to be part of software validation, and the <a href=\"https:\/\/www.fda.gov\/medical-devices\/digital-health-center-excellence\/device-software-functions-including-mobile-medical-applications\" target=\"_blank\" rel=\"noopener\">FDA&#039;s digital-health guidance<\/a> emphasizes tying security decisions to intended use and patient risk.<\/p>\n<p>Start with a threat model and data-flow map. Include mobile clients, APIs, identity providers, push services, cloud systems, analytics, and third-party SDKs. HHS&#039;s risk-analysis process calls for defining scope, gathering data, identifying threats and vulnerabilities, assessing safeguards, evaluating likelihood and impact, determining risk, and documenting safeguards. For each material risk, name an owner, control, verification test, and residual-risk decision.<\/p>\n<p><strong>Controls should address a specific hazard:<\/strong><\/p>\n<ul>\n<li><p><strong>Protect stored data:<\/strong> Use platform keystores and file-protection mechanisms to limit exposure if a device is lost.<\/p>\n<\/li>\n<li><p><strong>Protect connections:<\/strong> Enforce TLS for every connection and document whether certificate pinning is appropriate for the product&#039;s operational needs.<\/p>\n<\/li>\n<li><p><strong>Limit session exposure:<\/strong> Use OAuth 2.0 with PKCE and short-lived tokens where appropriate, then require passcode or biometric re-authentication after inactivity.<\/p>\n<\/li>\n<li><p><strong>Keep PHI out of secondary systems:<\/strong> Exclude health data from logs, crash reports, and push-notification previews unless the design and privacy analysis explicitly support its handling.<\/p>\n<\/li>\n<li><p><strong>Contain a lost-device incident:<\/strong> Support session revocation and remote wipe where the product&#039;s device-management model allows it.<\/p>\n<\/li>\n<\/ul>\n<p>Use OWASP MASVS and MASTG as testing references, combine static and dynamic analysis on representative devices, and commission penetration testing before release. Check analytics and crash-reporting SDKs against the data-flow map. Teams can also review Bridge Global&#039;s <a href=\"https:\/\/www.bridge-global.com\/services\/software-quality-assurance\">software quality assurance service<\/a> for the test-engineering side of release readiness. For patient-facing context, <a href=\"https:\/\/www.venushealth.co\/blogs\/fertility-wellness-journey\/data-security-and-privacy\" target=\"_blank\" rel=\"noopener\">health app data security<\/a> is a useful reference on privacy concerns.<\/p>\n<h2>Team and Delivery Models for Regulated Builds<\/h2>\n<p>Compare delivery options by decision authority, speed to start, and documentation ownership, not just by rate. The contract should identify who maintains the quality management system and risk file, who signs off clinical requirements, and who retains evidence after launch.<\/p>\n\n<figure class=\"wp-block-table\"><table><tr>\n<th>Delivery model<\/th>\n<th>Who holds control<\/th>\n<th>Speed to start<\/th>\n<th>Documentation after launch<\/th>\n<\/tr>\n<tr>\n<td>In-house team<\/td>\n<td>Your team owns the quality system and risk file<\/td>\n<td>Slowest, clinical and security hiring takes time<\/td>\n<td>Stays with your team<\/td>\n<\/tr>\n<tr>\n<td>Dedicated development team<\/td>\n<td>Your product owner directs the work<\/td>\n<td>Moderate, based on hiring and onboarding<\/td>\n<td>Defined by contract<\/td>\n<\/tr>\n<tr>\n<td>Full-cycle delivery<\/td>\n<td>Partner owns discovery through release<\/td>\n<td>Fast start, less internal knowledge built early<\/td>\n<td>Partner documents; transfer must be contracted<\/td>\n<\/tr>\n<tr>\n<td>Co-creation with in-house team<\/td>\n<td>Shared, partner fills specialist gaps<\/td>\n<td>Moderate<\/td>\n<td>Shared, with risk-file ownership agreed in advance<\/td>\n<\/tr>\n<\/table><\/figure>\n<p>A regulated build usually needs a product owner with clinical input, a mobile lead, a backend and integration engineer with FHIR experience, a QA engineer who can validate devices, a security engineer, and a regulatory or quality lead for device-classed products. Team size should follow scope and classification. Cost estimates are out of scope here; any budget figure should name team size, scope, region, and assumptions.<\/p>\n<p>Bridge Global offers <a href=\"https:\/\/www.bridge-global.com\/service-models\">software development service models<\/a>, including <a href=\"https:\/\/www.bridge-global.com\/service-models\/full-cycle-delivery-model-guide\">full-cycle software delivery<\/a> and <a href=\"https:\/\/www.bridge-global.com\/service-models\/corporate-business-solutions\">co-creation with in-house teams<\/a>. Our healthtech delivery combines European leadership with development teams in India. We can build a product from scratch or join an ongoing roadmap.<\/p>\n<p>Before choosing a partner, ask:<\/p>\n<ul>\n<li><p><strong>Design controls:<\/strong> How are requirements, risks, and verification evidence documented?<\/p>\n<\/li>\n<li><p><strong>Access:<\/strong> How is access to source code and infrastructure granted and removed?<\/p>\n<\/li>\n<li><p><strong>Release evidence:<\/strong> Is test evidence delivered with each release?<\/p>\n<\/li>\n<li><p><strong>Patient data:<\/strong> How is offshore access to patient data handled?<\/p>\n<\/li>\n<\/ul>\n<h2>Confirm Launch Readiness Before You Submit<\/h2>\n<p>The release owner should sign off on each gate before app-store submission. A successful build alone doesn&#039;t establish clinical readiness, privacy compliance, or safe behavior under failure.<\/p>\n<p><figure class=\"wp-block-image size-large\"><img decoding=\"async\" src=\"https:\/\/www.bridge-global.com\/blog\/wp-content\/uploads\/2026\/11\/healthcare-mobile-app-development-launch-checklist.jpg\" alt=\"A launch gate checklist for healthcare mobile applications, ensuring regulatory compliance, privacy, security, and clinical risk review.\" \/><\/figure><\/p>\n<ul>\n<li><p><strong>Intended use and classification:<\/strong> Product, clinical, and regulatory leads approve the statement and classification rationale.<\/p>\n<\/li>\n<li><p><strong>Requirements and tests:<\/strong> Each device-tier requirement maps to a test result in a complete requirements-to-test matrix.<\/p>\n<\/li>\n<li><p><strong>Security and residual risk:<\/strong> The threat model and penetration-test findings are closed or accepted in writing.<\/p>\n<\/li>\n<li><p><strong>Accessibility:<\/strong> Test WCAG 2.2 AA on commonly used phones and tablets, including a session with older users.<\/p>\n<\/li>\n<li><p><strong>Consent and deletion:<\/strong> Test privacy notices, consent and data-deletion flows end to end.<\/p>\n<\/li>\n<li><p><strong>Store declarations:<\/strong> Match Apple privacy labels and Google Play health declarations to actual data flows.<\/p>\n<\/li>\n<li><p><strong>Incident response:<\/strong> Document the response plan and publish a vulnerability-disclosure contact.<\/p>\n<\/li>\n<li><p><strong>Post-market monitoring:<\/strong> Track crashes, API failures, support requests, onboarding completion by age group, and 30-day retention.<\/p>\n<\/li>\n<\/ul>\n<p>Our healthcare app development lifecycle guide covers release sequencing, and the healthcare mobile app development overview provides broader market context. For release-quality planning, see our <a href=\"https:\/\/www.bridge-global.com\/blog\/medical-software-quality-assurance-guide\/\">medical software quality assurance guide<\/a>.<\/p>\n<p>Bridge Global built a HIPAA-compliant remote patient monitoring platform as a healthcare IoT application. Teams assessing a build can review our <a href=\"https:\/\/www.bridge-global.com\/healthcare\">custom healthcare software development<\/a> work and decide whether the delivery model fits their product and regulatory needs.<\/p>\n<h2>Frequently Asked Questions<\/h2>\n<h3>Does a healthcare mobile app always need FDA or MDR review?<\/h3>\n<p>No. Device review depends on the intended function and applicable market rules, not on the fact that the software runs on a phone. Appointment management and general wellness features may be treated differently from software that diagnoses, analyzes clinical data, or informs treatment.<\/p>\n<h3>Can a wellness app use HealthKit or Health Connect without device rules?<\/h3>\n<p>Health-data access alone doesn&#039;t automatically make an app a medical device. Intended use, claims, and how the app interprets or acts on the data determine the regulatory analysis.<\/p>\n<h3>Is native or cross-platform better for a monitoring app?<\/h3>\n<p>Cross-platform can work for shared screens and routine workflows. Continuous sensor communication, background synchronization, or device-specific behavior may call for native modules, with the final choice based on the app&#039;s device and validation requirements.<\/p>\n<h3>Which framework applies to an EU app with US users?<\/h3>\n<p>There isn&#039;t one framework that replaces all others. Assess the app&#039;s functions and data handling against the rules in each target market, then maintain a documented plan for the applicable privacy and device obligations.<\/p>\n<h3>What should we monitor after launch?<\/h3>\n<p>Track crashes, API failures, data-quality exceptions, support requests and workflow deviations. For patient-facing products, also review onboarding completion and retention so the team can identify where users need help.<\/p>\n<hr \/>\n<p>Bridge Global builds healthcare software for providers, healthtech startups and medical innovators, with systems designed for clinical workflows, data privacy and interoperability. We can build from scratch or contribute to an existing roadmap, so visit <a href=\"https:\/\/www.bridge-global.com\">Bridge Global<\/a> to discuss how your app&#039;s classification, integrations, and delivery model should shape the build.<\/p>\n<!-- AddThis Advanced Settings generic via filter on the_content --><!-- AddThis Share Buttons generic via filter on the_content -->","protected":false},"excerpt":{"rendered":"<p>What determines whether a healthcare mobile app needs a medical-device review, and how should that decision shape its technology stack? The answer starts with intended use: what the software does, what it claims to do, and how patients or clinicians &hellip;<!-- AddThis Advanced Settings generic via filter on get_the_excerpt --><!-- AddThis Share Buttons generic via filter on get_the_excerpt --><\/p>\n","protected":false},"author":224,"featured_media":58507,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1015],"tags":[1031,1142,1405,2069,2070],"class_list":["post-58508","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-healthcare","tag-healthcare-app-development","tag-hipaa-compliance","tag-fhir-integration","tag-mobile-app-tech-stack","tag-healthtech-app-security"],"featured_image_src":"https:\/\/www.bridge-global.com\/blog\/wp-content\/uploads\/2026\/11\/healthcare-mobile-app-development-digital-health.jpg","author_info":{"display_name":"Stephanie Cornelissen","author_link":"https:\/\/www.bridge-global.com\/blog\/author\/stephanie\/"},"_links":{"self":[{"href":"https:\/\/www.bridge-global.com\/blog\/wp-json\/wp\/v2\/posts\/58508","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.bridge-global.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.bridge-global.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.bridge-global.com\/blog\/wp-json\/wp\/v2\/users\/224"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bridge-global.com\/blog\/wp-json\/wp\/v2\/comments?post=58508"}],"version-history":[{"count":1,"href":"https:\/\/www.bridge-global.com\/blog\/wp-json\/wp\/v2\/posts\/58508\/revisions"}],"predecessor-version":[{"id":58512,"href":"https:\/\/www.bridge-global.com\/blog\/wp-json\/wp\/v2\/posts\/58508\/revisions\/58512"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.bridge-global.com\/blog\/wp-json\/wp\/v2\/media\/58507"}],"wp:attachment":[{"href":"https:\/\/www.bridge-global.com\/blog\/wp-json\/wp\/v2\/media?parent=58508"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.bridge-global.com\/blog\/wp-json\/wp\/v2\/categories?post=58508"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bridge-global.com\/blog\/wp-json\/wp\/v2\/tags?post=58508"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}